COX-2 expression in chondrosarcoma: a role for celecoxib treatment?

Area of Science:

• Oncology
• Biochemistry
• Pharmacology

Background:

• Chondrosarcomas are chemo- and radioresistant, with a subset arising from benign tumor syndromes like enchondromatosis (EC) and multiple osteochondromas (MO).
• Preventing tumor development in EC and MO patients could significantly improve prognosis.
• Cyclooxygenase-2 (COX-2) is implicated in various cancers, and its role in chondrosarcoma warrants investigation.

Purpose of the Study:

• To investigate the effect of selective COX-2 inhibition on chondrosarcoma growth.
• To assess COX-2 expression in central and peripheral cartilaginous tumors.
• To evaluate the efficacy of celecoxib, a COX-2 inhibitor, in chondrosarcoma cell lines and a xenograft model.

Main Methods:

• COX-2 protein expression was analyzed in cartilaginous tumors using immunohistochemistry and qPCR.
• Chondrosarcoma cell lines were treated with celecoxib and NS-398 to measure COX-2 activity (PGE(2) ELISA) and cell viability.
• A xenograft model using CH2879 cell line in immunoincompetent nude mice was used to study the in vivo effect of celecoxib over 8 weeks.

Main Results:

• High COX-2 protein expression was observed in solitary peripheral chondrosarcoma and EC-related central chondrosarcoma.
• Celecoxib treatment significantly decreased cell viability in three out of four high-grade chondrosarcoma cell lines after 72 hours.
• In vivo, celecoxib initially slowed tumor growth, but relapse occurred after prolonged treatment; tumor volume correlated negatively with celecoxib serum levels.

Conclusions:

• COX-2 is expressed in a significant portion of chondrosarcomas, supporting its role in tumor development.
• Celecoxib demonstrates in vitro efficacy by diminishing chondrosarcoma cell viability.
• While celecoxib shows initial promise in vivo, further investigation into its prophylactic potential and managing relapsed growth in EC and MO patients is crucial.